Stifel reiterated coverage on Morphic with a new price target
$MORF
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel reiterated coverage of Morphic with a rating of Hold and set a new price target of $33.00 from $61.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2023 | $46.00 | Buy | Citigroup |
| 9/25/2023 | $61.00 → $33.00 | Hold | Stifel |
| 9/25/2023 | Buy → Neutral | BTIG Research | |
| 8/9/2023 | $69.00 → $61.00 | Buy → Hold | Stifel |
| 9/7/2022 | $44.00 | Buy | Stifel |
| 7/20/2022 | $45.00 | Outperform | SVB Leerink |
| 3/31/2022 | $68.00 | Buy | Canaccord Genuity |
| 2/25/2022 | $82.00 → $76.00 | Outperform | RBC Capital |